Labcorp Holdings Inc.
Analysis
Labcorp is deliberately trading volume for margin: pushing mix into specialty testing and hospital partnerships, cutting the business that drags on profit, and raising guidance twice this year. The cost of that quality arrives in 2027, when Medicare payment cuts land. What would those payment cuts cost Labcorp in 2027?
- Labcorp is turning away business it used to chase.
On the Q2 call management said it would not chase low-price consumer testing because no one can see the price floor, and it dropped $50 million of sales that dragged on profit. That is why Diagnostic margins have risen five quarters.
- Specialty testing pulls a whole patient's testing along with it.
When a physician sends an oncology or Alzheimer's case to Labcorp, the routine bloodwork that patient needs later tends to follow, so tests per accession climbs while the price of a single test stays flat. How fast is neurology growing inside Diagnostics?
- Medicare payment cuts are a 2027 cost Labcorp has only partly answered.
The cuts were pushed off another year, but Labcorp plans for a $100 million hit to sales and profit in 2027 and has found only $25 million of savings to soften it. The RESULTS Act has backers in both parties but no score yet. Which tests would those payment cuts hit hardest?
- Specialty testing pulls routine volumeThe bull case rests on specialty testing, where oncology and neurology grow several times faster than routine work and pull a patient's other tests to Labcorp.
- Health system partnership pipelineHospital and regional laboratory partnerships keep adding patient volume, and management describes a pipeline of health systems still looking for a partner.
- Outlook raised each quarterManagement has raised its full-year revenue and profit outlook after each of the last several quarters, and Early Development has turned from shrinking to growing.
- PAMA cuts only delayedThe bear case is that PAMA reimbursement cuts remain in law, so the delay Labcorp received only pushes a revenue reduction into the next budget cycle.
- Growth depends on acquisitionsGrowth increasingly depends on buying hospital laboratory contracts, which begin at lower margins and require integration before they earn the company average.
- Uneven Early Development demandEarly Development demand has been unreliable for several years, and organic volume growth in the base diagnostics business stays in the low single digits.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Purchase | ≥$100K | May 11 | Jul 1 |
Donald Trump Republican · Executive | Sale | ≥$50K | Jan 12 | May 13 |
April McClain Delaney Democratic · House · MD-6 | Sale | ≥$1K | Aug 6 | Sep 9 |
April McClain Delaney Democratic · House · MD-6 | Sale | ≥$1K | Aug 7 | Sep 9 |
April McClain Delaney Democratic · House · MD-6 | Sale | ≥$1K | Aug 5 | Sep 9 |
Congressional trading data provided by QuiverQuant
How Labcorp Holdings turned $14.0B of revenue into $1.4B of operating income.
| Revenue | ||
|---|---|---|
| LabCorp Diagnostics | $10.9B | ▲ 7.22% YoY |
| Total revenue | $14.0B | |
| Gross profit | $4.0B | 28.8% |
| Operating income | $1.4B | 9.9% |